Bristol-Myers Squibb Company stock (US0897961004): EU label expansion for Opdivo follows solid Q1 earnings

Bristol-Myers Squibb Company shares on the NYSE trade near multi-week lows even as the US biopharma group secures a key European Commission label expansion for Opdivo in frontline advanced Hodgkin lymphoma and builds on Q1 2026 revenue growth.

Bristol-Myers Squibb Company, headquartered in Princeton, New Jersey and listed on the New York Stock Exchange under the ticker BMY, is in focus on 06/02/2026 after the European Commission approved a significant label expansion for its cancer drug Opdivo in frontline advanced classical Hodgkin lymphoma, while the stock continues to trade near a multi-week low in the United States.

According to a Bristol Myers Squibb press release dated 06/02/2026, the European Commission has approved Opdivo (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for adult and adolescent patients from 12 years of age with previously untreated Stage III or IV classical Hodgkin lymphoma, making this the first immunotherapy-based regimen available in the European Union for newly diagnosed advanced cHL.Bristol Myers Squibb press release as of 06/02/2026

The EC decision is based on Phase 3 SWOG 1826 (Study CA2098UT), which showed that Opdivo plus AVD reduced the risk of disease progression or death by 58% compared with brentuximab vedotin plus AVD, corresponding to a hazard ratio of 0.42 with a 95% confidence interval of 0.27 to 0.67 and a p-value of less than 0.0001, underlining the statistical robustness of the data cited by the company.Bristol Myers Squibb press release as of 06/02/2026

The stock price reaction on the US home market remains muted: data from Trading Economics indicate that BMY recently traded around USD 57.22, marking a roughly 17-week low and representing a decline of about 3.96% over the previous four weeks as of late May 2026, even though shares remain actively traded on the NYSE.Trading Economics as of 05/30/2026

For German investors, Bristol-Myers Squibb Company is also available via trading venues such as Tradegate and Frankfurt in euro, where quotations typically track the primary NYSE listing, although liquidity and quoted spreads can differ from the US market.

The label expansion in the European Union builds on a first quarter that already showed operational progress: for Q1 2026, Bristol Myers Squibb reported revenue of USD 11.49 billion, an increase of 2.6% year on year, with the top-line result coming in 7.4% above analyst expectations as summarized by sector commentary.StockStory earnings overview as of 05/2026

Management highlighted in its Q1 2026 communication that growth from newer products is helping to offset the impact of loss of exclusivity on older therapies, an important theme for large US pharmaceutical groups navigating patent cliffs and pricing pressures.

The combination of the Opdivo decision in Europe and the Q1 2026 revenue expansion underlines Bristol-Myers Squibb Company's role as a major US player in oncology and immunology, even though the current NYSE share price does not immediately reflect the latest regulatory milestone.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Bristol Myers Squibb
• Sector/industry: Biopharmaceuticals, focused on oncology, cardiovascular and immunology therapies
• Headquarters/country: Princeton, United States
• Core markets: United States, European Union, selected Asia-Pacific markets
• Key revenue drivers: Oncology and immunology medicines including Opdivo, Eliquis and other specialty therapies
• Home exchange/listing venue: New York Stock Exchange (BMY)
• Trading currency: USD

Bristol-Myers Squibb Company: core business model

Bristol-Myers Squibb Company generates most of its revenue by researching, developing, manufacturing and marketing innovative prescription medicines in areas such as oncology, cardiovascular disease and immunology, with a portfolio that leans heavily on specialty and targeted therapies.

Latest quarterly results for Bristol-Myers Squibb Company at a glance

In the most recently reported quarter, Q1 2026, Bristol-Myers Squibb posted revenue of USD 11.49 billion, representing a 2.6% increase compared with the same period a year earlier, according to an earnings summary that references the company's published figures.StockStory earnings overview as of 05/2026

The same source notes that this Q1 2026 revenue outcome exceeded analyst expectations by roughly 7.4%, suggesting that the market had anticipated softer sales than those ultimately delivered, even as investors continue to focus on the medium-term impact of patent expiries and pricing dynamics on the companys earnings profile.StockStory earnings overview as of 05/2026

Conclusion

The latest European Commission approval for Opdivo in combination with AVD in frontline advanced classical Hodgkin lymphoma underscores Bristol-Myers Squibb Company's strategic emphasis on oncology and consolidates its presence in the European market.

At the same time, Q1 2026 revenue growth and a top-line result ahead of consensus demonstrate that the US group continues to defend and expand its franchise, even as the NYSE-listed shares trade near multi-week lows and investors weigh longer-term patent and pricing risks.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.